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Background: Overexpression of ubiquitin-conjugating enzyme 2C (UBE2C) has been detected in many types of human
cancers, and is correlated with tumor malignancy. However, the role of UBE2C in human nasopharyngeal carcinoma
(NPC) is unclear. In this study, we investigated the role of aberrant UBE2C expression in the progression of human NPC.
Methods: Immunohistochemical analysis was performed to detect UBE2C protein in clinical samples of NPC and benign
nasopharyngeal tissues, and the association of UBE2C expression with patient clinicopathological characteristics was
analyzed. UBEC2 expression profiles were evaluated in cell lines representing varying differentiated stages of NPC and
immortalized nasopharyngeal epithelia NP-69 cells using quantitative RT-PCR, western blotting and fluorescent staining.
Furthermore, UBE2C was knocked down using RNA interference in these cell lines and proliferation and cell cycle
distribution was investigated.
Results: Immunohistochemical analysis revealed that UBE2C protein expression levels were higher in NPC tissues than in
benign nasopharyngeal tissues (P<0.001). Moreover, high UBE2C protein expression was positively correlated with tumor
size (P=0.017), lymph node metastasis (P=0.016) and distant metastasis (P=0.015) in NPC patients. In vitro experiments
demonstrated that UBE2C expression levels were inversely correlated with the degree of differentiation of NPC cell lines,
whereas UBE2C displayed low level of expression in NP-69 cells. Knockdown of UBE2C led to significant arrest at the S
and G2/M phases of the cell cycle, and decreased cell proliferation was observed in poorly-differentiated CNE2Z NPC
cells and undifferentiated C666-1 cells, but not in well-differentiated CNE1 and immortalized NP-69 cells.
Conclusions: Our findings suggest that high expression of UBE2C in human NPC is closely related to tumor malignancy,
and may be a potential marker for NPC progression.
Keywords: Nasopharyngeal carcinoma, Ubiquitin-conjugating enzyme 2C, Progression, Proliferation, Cell cycleBackground
Ubiquitination is a crucial molecular mechanism for the
degradation of short-lived proteins in eukaryotic cells,
and is involved in multiple cellular biological processes
including the cell cycle. The process of protein mo-
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reproduction in any medium, provided the orcontrol of three types of enzymes: E1 ubiquitin-activating
enzymes, E2 ubiquitin-conjugating enzymes and E3 ubi-
quitin ligase [1]. Human ubiquitin-conjugating enzyme
E2C (UBE2C, also called UBCH10) encodes a member of
the E2 ubiquitin-conjugating enzyme family [2]. It was
reported that UBE2C functions closely with the anaphase-
promoting complex/cyclosome (APC/C), which is an E3
ubiquitin ligase that targets cell cycle proteins for degrad-
ation by the proteasome [3]. UBE2C is required for the
destruction of mitotic cyclins, thereby participating in the
regulation of cell cycle progression through M phase [2].
In 2003, Okamoto et al. demonstrated that UBE2C
expression levels were extremely low in many normald. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinicopathological characteristics of patient






















M1 14 (15.4 )
Expression of UBE2C
High expression 51 (56.0)
Low expression 40 (44.0)
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lines examined, suggesting that UBE2C has the ability to
promote cell proliferation and malignant transformation
[4]. Recent data has shown that aberrantly high expres-
sion of UBE2C contributes to tumorigenesis, and has re-
vealed its potential as a biomarker for cancer prognosis
[5]. Abnormally high UBE2C expression was observed in
various human solid cancers in the liver [6], thyroid [7],
breast [8], colon [9,10], cervix [11], lung [12] and brain
[13], and UBE2C expression was positively correlated
with invasion depth and tumor node metastasis (TNM)
stage in some tumors. Furthermore, inhibition of UBE2C
expression induced by RNA interference significantly
reduced the proliferation of cancer cells [7,14] and en-
hanced cell apoptosis in vitro [15]. UBE2C transgenic
mice are prone to carcinogen-induced lung tumors and
a broad spectrum of spontaneous tumors, as UBE2C is a
prominent proto-oncogene [16]. Taken together, these
data suggest that targeting of UBE2C may be a potential
tool for tumor diagnosis and therapy.
Nasopharyngeal carcinoma (NPC) is a type of malig-
nant head and neck cancer derived from the nasopha-
ryngeal epithelium, and is one of the most common
malignant diseases in Southern China and Southeast
Asia [17]. Almost 85% of NPC patients display a more
advanced clinical stage of disease because of the preva-
lence of lymphadenopathy at first diagnosis [18]. The
process of NPC formation and metastasis is complex,
and various genes are involved [19] Therefore, it is of
great importance to research biomarkers for the early
diagnosis, prognosis prediction of NPC and to develop
novel therapeutic strategies for NPC. In the present
study, we aimed to investigate the role of UBE2C in the
progression of NPC. Our results indicated that detection
and targeting of UBE2C may be a potentially useful bio-
marker for NPC treatment.
Methods
Patient samples
One hundred and fifteen cases of paraffin-embedded
clinical samples were obtained from the Affiliated
Hospital of the Guangdong Medical College (Zhanjiang
City, Guangdong, China) and the People’s Hospital of
Zhongshan City (Zhongshan City, Guangdong, China).
In total, 91 cases of NPC (n=91) and 24 cases of naso-
pharyngeal epithelial hyperplasia (NEH) were examined
from 69 men (75.8%) and 22 women (24.2%). Clinical
stage was classified based on the pathology tumor–
node–metastasis (pTNM) system (AJCC⁄UICC 2002),
and all NPC samples were determined to be non-
keratinizing carcinoma. NPC patients were diagnosed for
the first time at an average age of 42.7 years (range, 23–
72 years). Additional clinical data are shown in Table 1.
The use of human tissues in this study was approved by theEthics Council of the Affiliated Hospital of the Guangdong
Medical College and the People’s Hospital of Zhongshan
City for Approval of Research Involving Human Subjects.
Immunohistochemical analysis of UBE2C protein
The expression and cellular distribution of UBE2C pro-
tein was assessed by immunohistochemical analysis. Five
micrometer-thick paraffin sections were deparaffinized
and re-hydrated according to standard protocols, and
heat-induced antigen retrieval was performed in sodium
citrate buffer (10 mmol/L, pH6.0). Endogenous peroxid-
ase was inhibited by 0.3% H2O2, and non-specific pro-
tein binding was blocked with 10% goat serum. Sections
were then incubated with primary antibody against
UBE2C (1:200 dilution; cat. #A-650, Boston Biochem,
MA, USA) at 4°C overnight. Non-immune IgG was used
as a negative control, and antigenic sites were localized
using a SP9000 Polymer Detection System and a 3,3′-
diaminobenzidine (DAB) kit (ZSGB-BIO, Beijing, China).
The immunoreactive score (IRS) of UBE2C was de-
scribed previously [20]. Briefly, the staining intensity was
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strong. The percentage of UBE2C-positive cells was
scored as 0, no cellular staining; 1, <1% cellular staining;
2, 1–10% cellular staining; 3, 10–33% cellular staining; 4,
33–66% cellular staining; and 5, >66% cellular staining.
Samples with a total IRS of <6 were deemed as having
low UBE2C expression, and samples with a sum IRS of
≥6 were determined as high UBE2C expression. The
scoring of UBE2C was evaluated individually and inde-
pendently by two pathologists who were double-blinded
to the clinical data.
Cell culture
CNE1, CNE2Z and C666-1 cell lines representing well-,
poorly- and undifferentiated NPC, respectively, were
grown in Dulbecco’s modified Eagle’s medium (DMEM;
Hyclone) supplemented with 10% fetal bovine serum (FBS;
Hyclone) and 100 U/ml penicillin and streptomycin
(100 μg/ml), as described previously [21]. The immortal-
ized nasopharyngeal epithelial cell line NP-69 (obtained
from the lab of Prof. Yao K.T., Cancer Research Institute,
Southern Medical University, Guangzhou, China) was cul-
tured in defined keratinocyte serum-free medium (cat.
#10744-019, Invitrogen) containing 100 U/ml penicillin,
100 μg/ml streptomycin, 0.2 ng/ml recombinant epider-
mal growth factor and 5% FBS. All cell lines were cultured
at 37°C in a humidified atmosphere with 5% CO2.
RNA interference
siRNAs were purchased from RiboBio Co., Ltd.
(Guangzhou, China). For RNA interference (RNAi) ex-
periments, the following double-stranded oligo RNAs
specific for the UBE2C coding region (si-UBE2C) were
used: forward, 5′-GGACACCCAGGGUAACAUAdTdT-3′,
reverse, 5′-UAUGUUACCCUGGGUGUCCdTdT-3′.
A corresponding scrambled sequence (si-Control, Cat.
siB05815) was used as a negative control. One day before
transfection, equal numbers of CNE1, CNE2Z, C666-1 and
NP-69 cells (5.0×105/ml) were seeded in 6-, 24- and 96-well
plates supplemented with complete medium without anti-
bodies. When cells had reached 60–70% confluency, they
were transfected with siRNAs using Lipofectamine 2000
(Invitrogen) in Opti-MEM I medium (Invitrogen). Cells
were incubated at 37°C in a humidified atmosphere of 5%
CO2 for 6 h followed by replacement of complete medium.
The efficiency of transfection was verified by observation
of the fluorescence emitted by the Cy3-conjugated
si-Control using fluorescence microscopy.
Immunofluorescent staining
Indirect immunofluorescence was performed on NPC cells
cultured on glass coverslips. After overnight incubation
with primary antibody against UBE2C (1/100) at 4°C, the
antigenic sites were detected using TRITC-conjugated goatanti-rabbit IgG (1/100, Protein Tech Group, Inc., Chicago,
IL, USA). Images of the antigenic sites were captured with
a laser scanning confocal microscope (TCS SP5 II; Leica,
Germany).
Western blotting
Total proteins were extracted using RIPA lysis buffer (Cat.
# P0013C, Beyotime Institute of Biotechnology, Jiangsu,
China). 30 μg total proteins were subjected to SDS-PAGE,
and then proteins were transferred to the PVDF membranes.
After twice washed with TBST, the membranes were incu-
bated with 5% skimmed milk in TBST at 37°C for 30 min,
then the membrane were incubated with the primary anti-
bodies (UBE2C, 1:500, Boston Biochem; β-actin, 1:1000,
Santa Cruz, Texas, USA) at 4°C overnight, After twice
washed by TBST, the membranes were incubated with horse-
radish peroxidase (HRP)-conjugated secondary antibodies for
1 hour at 37°C. Bands were visualized using enhanced chemi-
luminescence (ECL) reagents (Thermo Fisher, Rockford, IL,
USA) and analyzed with gel analysis system (BIO-RAD
VersDoc TM5000MP System, Guangzhou, China). The
expression of β-actin was used as loading control.
RNA extraction and quantitative RT-PCR
Total RNA was extracted with TaKaRa RNAiso plus re-
agent (Takara Biotechnology (Dalian) Co., Ltd.). Next,
1 μg of total RNA was used as a template to generate the
first strand cDNA by oligo(dT18) using the Promega RT
System. Pairs of primers (5′–3′) synthesized by Sangon
Biotech Co., Ltd. (Shanghai, China) were as follows:
UBE2C forward: tgatgtctggcgataaagggatt, UBE2C reverse:
gtgatagcagggcgtgaggaa. β-actin forward, tgacgtggacatccgc
aaag, β-actin reverse, ctggaaggtggacagcgagg. PCR was
conducted using the LightCycler480 II instrument (Roche
(China) Ltd., Shanghai, China). The total reaction volume
of 10 μl consisted of 5 μl SYBR Green I PCR Master Mix
(Toyobo, Osaka, Japan), 0.4 μl forward primer (10 μM),
0.4 μl reverse primer (10 μM), 1 μl cDNA and 3.2 μl
ddH2O. The PCR amplification protocol was as follows:
denaturation was performed at 95°C for 1 min, followed
by 45 PCR cycles of 95°C for 15 s, and 60°C for 60 s. The
relative abundance of target mRNAs were determined
from the CT values and plotted as the fold change com-
pared with the control group.
In vitro proliferation assays
Proliferation rates were determined by Cell Counting Kit-8
(CCK-8) assays, as described previously [21]. Briefly, 4×103
cells were seeded in 96-well plates at either 24 and 48 h
after transfection with or without siRNAs, then 10 μl CCK-
8 reagent (Beyotime Institute of Biotechnology, Jiangsu,
China) plus 100 μl basal DMEM medium was added per
well, and the absorbance of the samples was measured.
Each independent experiment was performed three times.
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NPC cell lines were seeded in 6-well plates and were
successfully transfected in triplicate for each set of ex-
perimental conditions with the siRNAs described above.
Forty-eight hours later, harvested cells were stained with
propidium iodide (PI) and subjected to flow cytometric
analysis (BD FACSCanto II, MA, USA).Statistical analyses
Statistical analyses were carried out using PRISM Soft-
ware (Version 5. GraphPad Software, CA, USA). Data
were analyzed with Chi-square tests and expressed as
mean ± SD. For analysis of the differences between two
groups, Student’s t-tests were performed. For multiple
groups, ANOVA was carried out followed by Student–
Newman–Keuls tests. The level of statistical significance
was set at P<0.05.Results
Immunohistochemical analysis of UBE2C protein
expression in NPC and nasopharyngeal tissues
First, we investigated the expression of UBE2C in NEH
and NPC. Immunohistochemical staining revealed that the
majority of NEH cases displayed no or low levels of UBE2C
protein expression (IRS <6, 24/24); however, 56% of NPCs
(51/91) exhibited strong nuclear and cytoplasmic UBE2C
immunoreactivity (IRS ≥6) (P<0.001 when compared withCase 1
Case 3
Figure 1 Representative photographs of high UBE2C expression in NP
nasopharyngeal epithelial hyperplasia (NEH). The immunohistochemica
clinical samples. Non-immune IgG was used as a negative control. The expr
DAB and counterstaining with hematoxylin. IRS >6.0 in NPC (cases 1 & 2) an
for the IgG control, ×100. Scale bar = 100 μM.NEH), indicating a crucial role of UBE2C expression in the
pathogenesis of NPC (Table 1 and Figure 1).Relationship between clinicopathological characteristics
and UBE2C protein expression in NPC patients
The relationships between clinicopathological parameters
and UBE2C protein expression levels in NPCs are de-
tailed in Table 2. There was no significant association of
high UBE2C protein expression levels with age, sex,
smoking and clinical stage (I–II vs. III–IV) in 91 NPC
cases. However, we observed that the level of UBE2C
protein expression was positively correlated with tumor
size (T classification) (T1–T2 vs. T3–T4, P=0.017), lymph
node metastasis (N classification) (N0 vs. N1–N3)
(P=0.016) and distant metastasis (M classification) (M0 vs.
M1, P=0.015) in NPC patients (Table 2). These data indi-
cated that UBE2C overexpression may be associated with
the clinical progression of NPC.Expression profiles of UBE2C in NPC cell lines in vitro
CNE1, CNE-2Z and C666-1 cells were used to further
examine the expression profiles of UBE2C in NPC cell
lines in the present study. As shown in Figure 2, variable
expression of UBE2C was observed at both the mRNA
and protein levels in various NPC cell lines. In general,
lower expression of UBE2C was detected in highly dif-
ferentiated CNE1 cells, while increasing expression levelsCase 2
IgG control
C samples and low UBE2C expression in non-cancerous
l PV9000 method was used to detect UBE2C protein expression in
ession and location of UBE2C in cells was revealed by staining with
d IRS <6.0 in NEH (case 3). Original magnification for cases 1–3, ×200,
Table 2 Correlation between clinicopathological






NPC 91 51 40
26.80 0.0001*
NEH 24 0 24
Smoking
Yes 42 24 18
0.038 0.845
No 49 27 22
Gender
Male 69 37 32
0.679 0.410
Female 22 14 8
Age
≧50 44 22 22
1.263 0.261
< 50 47 29 18
Clinical classification
I–II 15 6 9
1.877 0.171
III–IV 76 45 31
T classification
T1–T2 31 12 19
5.735 0.017*
T3–T4 60 39 21
N classification
N0 19 6 13
5.835 0.016*
N1-N3 72 45 27
M classification
M0 77 39 38
5.913 0.015*
M1 14 12 2



















Figure 2 UBE2C expression in variously differentiated NPC cell
lines and NP-69 cells. (A) Well-differentiated CNE1 cells, poorly-
differentiated CNE2Z cells, undifferentiated C666-1 cells and
immortalized NP-69 cells were seeded in triplicate in 24-well plates
for each cell line (n=3), and were harvested for the analysis of UBE2C
mRNA expression by qRT-PCR; β-actin was used as a loading control.
**P<0.01 vs. NP-69, # P<0.05 vs. CNE1, ΔP<0.05 vs. CNE2Z. (B) Western
blotting analysis the UBE2C protein expression in CNE1, CNE2Z,
C666-1 and NP-69 cells. β-actin was used as a loading control.
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entiated NPC) and C666-1 cells (undifferentiated NPC).
Low level of UBE2C expression was also observed in im-
mortalized NP-69 cells (Figures 2 and 3). These results
indicated that UBE2C was universally expressed in the
NPC cell lines, and its expression levels were inversely
associated with differentiation status. Finally, immuno-
fluorescent staining showed that UBE2C protein was cyto-
plasmic in immortalized NP-69 cells, but localized to the
cytoplasm and nuclei of NPC cell lines (Figure 3).
Knockdown of UBE2C attenuates NPC proliferation
Forced UBE2C expression in NIH 3T3 cells has been
shown to promote cell proliferation [4]. Thus, we exam-
ined the role of UBE2C in NPC cell proliferation. Three
pairs of RNA oligos targeting different regions of the
UBE2C gene coding region were designed to knockdown
UBE2C expression (data not shown). We found that thedouble-stranded oligos targeting the sequence GGACACC
CAGGGTAACATA (401–420nt of CDS of UBE2C)
displayed the most powerful inhibitory effects (>75%). As
shown in Figure 4A, si-UBE2C attenuated UBE2C expres-
sion both at the mRNA and protein levels in high UBE2C-
expressing C666-1 cells, indicating these siRNA oligos
function well. Therefore, these double-stranded RNA
oligos were used in the subsequent experiments. And the
results of western blotting further confirmed that transfec-
tion this siRNAs to NPC cells led to a significant decrease
of UBE2C protein expression (Figure 4B). Then the cell
proliferation was examined by CCK-8 assays post transfec-
tion these 4 cell line with UBE2C specific siRNA. As
shown in Figure 4C, transfection of the NPC cell lines
with this siRNA led to significantly damaged cell viability
in CNE2Z and C666-1 cells, but not the CNE1 and NP-69
cells. Together, these results suggest that overexpression























Figure 3 Representative fluorescent photographs of UBE2C protein expression in various NPC cell lines and NP-69 cells. Cells grown on
glass coverslips were incubated with primary rabbit-anti human UBE2C antibody overnight; the antigenic site of UBE2C was located by TRITC-
conjugated goat anti-rabbit IgG (H+L) and photographed by confocal microscopy. Scale bars = 100 μM.
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phases
UBE2C is involved in many points of cell cycle control
[5]. In the present study, treatment of the NPC cell lines
with si-UBE2C decreased the distribution of cells in G1
phase but increased the proportion in S and G2/M
phase. As shown in Figure 5, the increases in the pro-
portion of NP-69, CNE1, CNE2Z and C666-1 cells in S
phase was 35.7%, 30.9%, 79.9% and 141.6%, respectively.
Furthermore, the increase in the proportion of NP-69,
CNE1, CNE2Z and C666-1 cells in G2/M phase was
26.4%, 21.1% 92.8% and 110.3%, respectively. These re-
sults suggested that inhibition of UBE2C expression in
UBE2C highly-expressing NPC cells led to a significant
re-distribution in the cell cycle.
Discussion
In the present study, we first found that UBE2C was pre-
dominantly expressed in NPC samples, whereas it was
weakly expressed in nasopharyngeal tissues; moreover, we
found that high UBE2C protein expression was positively
related to tumor size, lymph node metastasis and distant
metastasis in NPC patients. These results indicated that
high expression of UBE2C was closely related to the clin-
ical progression of NPC. Consequently, we examinedUBE2C expression in variously differentiated NPC cell
lines in vitro. The results showed that immortalized naso-
pharyngeal NP-69 cells displayed low level of UBE2C ex-
pression; however, UBE2C was universally expressed in a
variety of NPC cell lines, and its expression levels were
reversely related to the stages of differentiation. Finally,
treatment of the NPC cells with UBE2C-specific siRNA
led to a decrease in cell proliferation and arrest at S and
G2/M phase of the cell cycle, suggesting that targeting of
UBE2C is a potential anti-NPC therapeutic strategy. To
the best of our knowledge, this is the first report regarding
the relation of aberrant expression of UBE2C with NPC
malignancy.
Human UBE2C belongs to the E2 ubiquitin-conjugating
enzyme family [2], which functions closely with APC/C
[3]. Expression of UBE2C is required for the destruction
of mitotic cyclins, for example cyclin B, to promote cell
cycle progression from M to G1 phase [2]. Therefore,
overexpression of UBE2C contributes to increased cell
proliferation, and as a result, cancer cells acquire a hall-
mark of tumorigenicity through uncontrolled cell prolifer-
ation. Early work by Fang et al. revealed that some
candidate biomarkers for cancer, including UBE2C, were
upregulated in NPC [22]. In the present study, we found















































Figure 4 siRNA inhibited UBE2C expression in NPC cells and consequently resulted in attenuated cell proliferation. (A) C666-1 cells were
transfected with si-UBE2C or si-Control or without siRNA (MOCK). Forty-eight hours later, UBE2C expression was assessed by PCR and
immunofluorescence using TRITC-conjugated IgG (H+L). (B) Western blotting analysis the UBE2C protein expression in various cell lines post
tranfection of siRNAs, the β-actin was used as loading controls. (C) Twenty-four and 48 h after transfection, CCK-8 assays were used to analyze the
proliferation of various types of NPC cells. Values of optical density (OD) were obtained by the absorbance at the dual wavelengths 450/630 nM,
and the results indicating the cell viability were plotted as the percentage over controls (MOCK cells). * P<0.05, ** P<0.01 vs. mock or
si-Control–treated groups.
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http://www.biomedcentral.com/1471-2407/13/19256.0% NPC cases, whilst no UBE2C expression was ob-
served in benign nasopharyngeal tissues; moreover, high
UBE2C expression was found to be positively associated
with the T, M and N classifications of NPC, indicating that
high expression of UBE2C contributes to the pathogenesis
and clinical progression of NPC, although these findings re-
quire further validation in larger cohorts. Our results were
consistent with other reports describing overexpression of
UBE2C in many types of tumors, and demonstrate that de-
tection of UBE2C may be a potential biomarker for tumor
diagnosis or prognostic judgment [6-9,13,20,23-29].
By using a variety of differentiated stages of NPC cell
lines, the UBE2C expression profiles were further analyzed.
Well-differentiated CNE1, poorly-differentiated CNE2Zand undifferentiated C666-1 cells used in the present
investigation were representative of NPC. We found that
when compared with the immortalized NP-69 cells,
UBE2C mRNA and protein were universally expressed in
these NPC cell lines. Generally, UBE2C expression was
found to be inversely related with the differentiation stages
of NPC cells. Poor differentiation in cancer cells implies a
higher degree of malignancy, and as a hallmark of tumori-
genesis, upregulated cell proliferation and migration was
acquired. As a result, after treatment of the NPC cell lines
with UBE2C-specific siRNA, attenuated cell proliferation
was observed. Our results revealed that targeting UBE2C
in NPC cells may be beneficial for NPC molecular treat-
ment. These in vitro results were also consistent with other
G1  68.1%
S   27.8%
G2/M   4.2%
G1   69.1%
S    25.2%
G2/M   4.6%
G1  48.2%
S   44.8%
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G1   66.5%
S    29.7%
G2/M    3.8%
G1   68.6%
S    29.1%
G2/M    2.2%
G1   54.6%
S    38.9%
G2/M    4.6%
Figure 5 Knockdown of UBE2C with siRNA arrested the cell cycle at G2-M and S phase. CNE1, CNE2Z, C666-1 and NP-69 cells were
transfected with UBE2C siRNA (si-UBE2C) or si-Control or left untransfected (MOCK) for 48 h, then the cell cycle was assessed by FCM.
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strategy in various cancers, such as cervical, colorectal and
esophageal carcinomas [11,14,25,30,31].
Cell cycle progression is precisely mediated by a combin-
ation of cyclin-dependent kinases, kinase inhibitors and
protein phosphorylation. The timely and specific degrad-
ation of cyclins and kinase inhibitors at critical check
points in the cell cycle by the ubiquitin-proteasome system
(UPS) also participates in this process. The cell-cycle G2-M
phase gene UBE2C encompasses the cell cycle window as-
sociated with exit from mitosis. Depletion of UBE2C in
cancer cells by UBE2C-siRNA redistributes the cell cycle
phases [14,25], while bortezomib or cell-cycle inhibitor-779
(CCI-779) stabilizes mitotic cyclins and prevents cell cycle
progression via attenuation of UBE2C transcription andmRNA stability [30,32]. Our present results revealed that
knockdown of UBE2C in NPC cells caused significant cell-
cycle G2-M and S accumulation. As our results show,
transfection of the most highly UBE2C-expressing C666-1
cells with siRNA for 48 h lead to a 141.6% increase in G2-
M and 110.3% increase in S phase, implying a crucial role
of UBE2C in NPC cell cycle determination. Our results
support the findings of Lin et al., who reported that inhib-
ition of UBE2C in Seg-1 cells with si-UBE2C resulted in
the re-distribution of the cell cycle [25].
The UBE2C gene is localized to 20q13.1, a chromosomal
region frequently associated with genomic amplification in
many types of cancers. It was reported that genomic amp-
lification was a mechanism of increased UBE2C expres-
sion in colon cancer, thyroid carcinoma and prostate
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aberrations were also observed in NPC [35,36]. High fre-
quencies of allelic imbalances at chromosomes 3p, 9p,
11q, 12q, 13q, 14q, and 16q were detected in primary
NPC [37]. Very recently, Hu et al. reported a series of
chromosomal abnormalities, including some of those hot
spots mentioned above, in C666-1 cells and NPC biopsies
[38]. In contrast to the previous investigations regarding
amplification of 20q in some human tumors [23,33,34],
the loss of 20q in NPC was reported by Yan et al. [39]. We
did not examine the amplification of 20q in the present
study; thus, the mechanism of high expression of UBE2C
in NPC requires further elucidation.
NPC is an Epstein Barr virus (EBV) associated malig-
nant carcinoma. The EBV- positive NPC cells display
much aggressiveness, which has been reported previously
by various labs. It was reported that in papillomavirus type
16 E6- and E7- expressing keratinocytes, a high expression
of UBE2C was observed, which may lead to the bypass of
the spindle assembly checkpoint even with the DNA
injury [40]. In NPC cells, EBV may impair cell cycle
checkpoint via its encoded lament membrane protein [41].
Thus, the possible relationship between the infection of
EBV and up-regulation of UBE2C in NPC should deserver
much attention.
Conclusions
We provided the first evidence that high UBE2C expres-
sion is closely related to the clinical progression of NPC.
UBE2C was universally expressed in all NPC cell lines
examined, and its expression levels were inversely related
with cell differentiation; knockdown of UBE2C by specific
siRNA led to attenuated cell proliferation and cell cycle
arrest at G2-M and S phases. Our results indicated that
detection and targeting of UBE2C may be beneficial for
NPC treatment.
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